Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5R01CA233481-02
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
National Institutes of Health
Grant: 5R01CA200919-02
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA
National Institutes of Health
Grant: 1R01CA218008-01A1
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
National Institutes of Health
Grant: 1R21CA195077-01A1
ANOIKIS EFFECTORS AS DRIVERS OF METASTATIC MELANOMA
National Institutes of Health
FWCI
0.59
Citation Percentile
0.6%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals